Business Context and Reporting Period
Company: AYTU BIOPHARMA, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: February 21, 2023
Subject: Non-reliance on previously issued financial statements for the quarter ended September 30, 2022, due to accounting errors regarding warrant classification.
Key Financial Metrics and Adjustments
This filing does not report standard operational metrics (revenue, cash flow) but details specific accounting adjustments required for the quarter ended September 30, 2022:
- Total Liabilities Adjustment: Increase of $5.6 million.
- Shareholder's Equity Adjustment: Decrease of $3.4 million.
- Net Loss Adjustment: Reduction of the net loss by approximately $2.2 million (due to a gain from fair value adjustment of derivative warrant liabilities).
- Root Cause: Misclassification of outstanding warrants as equity components instead of liabilities.
Material Changes and Restatement Details
The Audit Committee concluded that the interim unaudited consolidated financial statements for the quarter ended September 30, 2022, should be restated. The company determined the error was not material to the Form 10-Q for the quarter ended March 31, 2022, nor the Form 10-K for the fiscal year ended June 30, 2022. Consequently, only the September 30, 2022, statements and future filings will be adjusted to reflect warrants as liabilities.
Outlook, Risks, and Management Commentary
- Internal Controls: The company has identified a material weakness in its internal control over financial reporting and is actively working to remediate it.
- Future Filings: Management expects to file an amendment (Form 10-Q/A) for the quarter ended September 30, 2022, and the Form 10-Q for the quarter ended December 31, 2022, as soon as practicable.
- Operational Impact: Going forward, unless warrant terms are amended, the company must measure the fair value of warrant liabilities, which may adversely affect results of operations.
- Risks: Potential SEC inquiry regarding the restatements or accounting practices; timing uncertainties of the restatement process.
Investor Verification Checklist
- Verify the filing of the Form 10-Q/A for the quarter ended September 30, 2022, to confirm the restated financial figures.
- Monitor the upcoming Form 10-Q for the quarter ended December 31, 2022, for continued liability classification of warrants.
- Review future disclosures regarding the remediation plan for the identified material weakness in internal controls.
- Watch for any announcements regarding an SEC inquiry into the company's accounting practices.